BILIARY TRACT CANCER

This study tests a drug called ivosidenib, combined with lenvatinib or an immunotherapy, for people with advanced bile duct cancer that has a specific IDH1 gene change and has stopped responding to standard chemotherapy. The goal is to see if this targeted approach can shrink tum…

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…

This study is for people with bile duct or gallbladder cancer that cannot be removed by surgery. It tests whether adding immunotherapy (adebrelimab) and a targeted drug (apatinib) to a special chemotherapy routine can help patients live longer. About 124 participants will receive…

This study tests a new treatment called RP2, a virus that attacks cancer cells and boosts the immune system, combined with other drugs for people with advanced liver or bile duct cancer that has not responded to first-line therapy. About 60 adults will receive RP2 alone or with s…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific protein (CLDN18.2). The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, bile duct, or pancreatic cancer…

This study tests whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can help people with bile duct or gallbladder cancer. About 45 adults with tumors that can be surgically removed will receive 2-4 cycles of the combinati…

This study is for people with advanced biliary tract cancer (a type of bile duct cancer) that has not responded to other treatments. It tests a combination of two drugs, AK130 and AK112, to see if they are safe and can shrink tumors. The study has two parts: first, finding the be…

This study tests a combination of two experimental drugs, HX009 and IN10018, with or without standard chemotherapy, in people with advanced solid tumors like bile duct cancer and melanoma that have not responded to prior treatments. The goal is to find the best dose and see if th…

This study tests a new combination of two chemotherapy drugs (trifluridine/tipiracil pills plus oxaliplatin by IV) in people with advanced or metastatic biliary tract cancer whose first treatment stopped working or didn't help. The goal is to see if this combo controls the cancer…

This study tests whether a new drug called rilvegostomig, combined with chemotherapy, works better than another immunotherapy (durvalumab) with the same chemo for people with advanced biliary tract cancer. About 1100 adults whose cancer cannot be removed by surgery or has spread …

This early-phase trial tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part.

This study looks at the safety of the drug Tasfygo in 60 people with advanced biliary tract cancer that has a specific gene change (FGFR2 fusion) and has gotten worse after chemotherapy. Researchers will track side effects and how well the drug works. The goal is to make sure Tas…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests if a new drug called ivonescimab works better than standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 patients who were part of a previous trial will receive either ivonescimab or chemother…

This study tests a new drug called MK-2870, alone or with other cancer treatments, for people with advanced colorectal, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The main goals are to check the drug's safety and see how many patients' tumo…

This study is for people who have had surgery for biliary tract cancer. It uses a special test called MiniPDX to see which chemotherapy drugs might work best for each person. The goal is to see if this personalized approach can help prevent the cancer from coming back. About 204 …

This study tests whether combining two drugs, ligufalimab and cadonilimab, can shrink tumors in people with advanced liver or bile duct cancers that no longer respond to standard treatments. About 64 adults will receive the drug combination to see if it improves response rates an…

This early-phase study tests an experimental drug called BL-M05D1 in 160 adults with advanced or metastatic solid tumors, including stomach, pancreatic, esophageal, and bile duct cancers. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This study tests a new drug called datopotamab deruxtecan (Dato-DXd) alone or with other cancer drugs in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gas…

This study tests whether adding zanidatamab to standard chemotherapy (with or without an immunotherapy drug) helps people with advanced HER2-positive biliary tract cancer live longer without their cancer growing. About 286 participants will be randomly assigned to receive either …

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This study tests a combination of two targeted drugs (trastuzumab and serplulimab) plus chemotherapy in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this triple therapy can shrink tumors and improv…

This study tests a new drug, SHR-A1904, in people with advanced bile duct cancer that has not responded to previous treatments. The drug targets a specific protein (CLDN18.2) on cancer cells. About 151 participants will receive the drug to see if it can shrink tumors or slow dise…

This early-phase study tests an experimental drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe and can shrink tumors in cancers like breast, lung, stomach, and ovarian cancer. Participants must have tr…

This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent dir…

This study tests new immune-boosting drugs, alone or with other cancer treatments, in people with advanced liver or bile duct cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 294 adults whose cancer has spread or cannot be removed by surger…

This study tests a new drug called TQB2102 in people with advanced bile duct cancer that has a specific marker (HER2-positive). The goal is to see if the drug can shrink tumors or slow the cancer's growth, and to check for side effects. About 102 adults aged 18 to 75 will take pa…

This study tests a new drug called AZD4360 in adults with advanced solid tumors, including stomach, gastroesophageal junction, bile duct, and pancreatic cancers that have not responded to prior treatments. The main goals are to find a safe dose and check for side effects, while a…

This study tests three common pain management methods used during minimally invasive cancer surgery. About 48 adults having surgery for cancers like liver, stomach, or colorectal cancer will be randomly assigned to one of three groups: a nerve block with numbing medicine, the ner…

This study tests whether using virtual reality (VR) can reduce severe belly pain in people with digestive tract cancers. 360 participants will be split into three groups: one using skills-based VR, one using distraction VR, and a sham control group. Researchers will track pain, a…

This study looks at whether a blood or stool test that detects tumor DNA (called ctDNA) can help doctors better manage gastrointestinal cancers like pancreas, colon, and bile duct cancer. About 100 adults with these cancers will provide samples, and researchers will track surviva…

This study is testing whether a simple blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive for doctors to choose targeted treatments. The study wi…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy does. Researchers will enroll 200 adults with advanced biliary tract cancer across multiple hospitals in Korea.…

This study is for people with advanced biliary tract cancer (a type of bile duct cancer) who are scheduled to receive a combination of two drugs, lenvatinib and pembrolizumab. Researchers want to find genetic markers in blood and tumor samples that might predict how well a person…

This study is exploring whether certain Helicobacter bacteria (like H. pylori) are more common in people with biliary tract cancers than in those with non-cancerous gallbladder conditions. Researchers will test tissue samples from 250 participants, including cancer patients, peop…